<DOC>
	<DOCNO>NCT02574377</DOCNO>
	<brief_summary>This interventional study test immunogenicity combine adjuvant myDC pDC vaccination versus adjuvant myDC pDC vaccination alone stage III melanoma patient .</brief_summary>
	<brief_title>myDC/pDC Stage III Melanoma Patients</brief_title>
	<detailed_description>Stage lll melanoma patient receive pDC ( arm A , n=10 ) , myDC ( arm B , n=10 ) combine pDC/myDC ( arm C , n=10 ) . Subsequent vaccination perform accord protocol : 2 biweekly vaccination intranodal injection pDC , myDC combination pDC myDC . After vaccination investigator examine peripheral blood proliferative humoral KLH immune response . After vaccination , DTH peptide load blood DC perform biopsy take T cell analysis . lf patient remain disease free , investigator repeat cycle 6 month interval total three cycle . lf tumor recurrence occur biopsy take laboratory evaluation .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>stage III melanoma WHO performance status 01 radical lymph node dissection schedule perform within 12 week prior start study treatment irresectable disease concurrent adjuvant therapy concomitant use oral immunosuppressive drug autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>